{
    "organizations": [],
    "uuid": "dc096da27dfead2bb930e9d3feb7bd965d122e5c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-adaptimmune-reports-q1-loss-per-sh/brief-adaptimmune-reports-q1-loss-per-share-0-04-idUSASC0A0XT",
    "ord_in_thread": 0,
    "title": "BRIEF-Adaptimmune Reports Q1 Loss Per Share $0.04",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 9, 2018 / 11:36 AM / in 7 minutes BRIEF-Adaptimmune Reports Q1 Loss Per Share $0.04 Reuters Staff\nMay 9 (Reuters) - Adaptimmune Therapeutics PLC:\n* ADAPTIMMUNE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE * Q1 REVENUE $8.2 MILLION\n* Q1 EARNINGS PER SHARE VIEW $-0.24, REVENUE VIEW $9.1 MILLION â€” THOMSON REUTERS I/B/E/S\n* GUIDANCE CONFIRMED, FUNDED THROUGH TO EARLY 2020 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-05-09T14:34:00.000+03:00",
    "crawled": "2018-05-09T14:51:39.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "minute",
        "report",
        "q1",
        "loss",
        "per",
        "share",
        "reuters",
        "staff",
        "may",
        "reuters",
        "adaptimmune",
        "therapeutic",
        "plc",
        "adaptimmune",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "business",
        "update",
        "q1",
        "revenue",
        "million",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "guidance",
        "confirmed",
        "funded",
        "early",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}